Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Oncternal Therapeutics Inc (ONCT)

Oncternal Therapeutics Inc (ONCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer GlobeNewswire - Tue Oct 22, 8:00AM CDT

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 8, 3:20PM CDT

Oncternal Therapeutics: Q2 Earnings Snapshot

ONCT : 1.1600 (+1.75%)
Wall Street - NYSE Stock Market American Flag
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus Barchart - Tue Apr 4, 2023

June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 339.64 (-0.70%)
VORB : 0.0769 (-34.83%)
OKYO.LN : 1.400 (-24.32%)
BFLY : 3.29 (-0.90%)
AMC : 4.49 (+1.13%)
ONCT : 1.1600 (+1.75%)
EVO : 5.35 (+0.94%)
HLN : 9.55 (+0.74%)
CRBG : 31.47 (+2.71%)
Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Transcript Motley Fool - Wed Aug 10, 2022

ONCT earnings call for the period ending June 30, 2022.

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results Globe Newswire - Tue Aug 9, 2022

Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to...

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results Globe Newswire - Tue Aug 2, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL Globe Newswire - Thu Jul 14, 2022

Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab...

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress Globe Newswire - Fri Jun 10, 2022

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress Globe Newswire - Fri Jun 10, 2022

SAN DIEGO, June 10, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 1.1600 (+1.75%)
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 Globe Newswire - Thu Jun 2, 2022

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...

ONCT : 1.1600 (+1.75%)

Barchart Exclusives

Up 882% YTD, Is It Too Late to Buy This Fintech Stock? Barchart - 7 minutes ago
A recent guidance boost from DAVE propelled the stock even higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot